MONTAIR 5 MG

Land: Israel

Språk: engelska

Källa: Ministry of Health

Köp det nu

Bipacksedel Bipacksedel (PIL)
17-08-2016

Aktiva substanser:

MONTELUKAST AS SODIUM

Tillgänglig från:

CTS CHEMICAL INDUSTRIES LTD, ISRAEL

ATC-kod:

R03DC03

Läkemedelsform:

CHEWABLE TABLETS

Sammansättning:

MONTELUKAST AS SODIUM 5 MG

Administreringssätt:

PER OS

Receptbelagda typ:

Required

Tillverkad av:

CTS CHEMICAL INDUSTRIES LTD, ISRAEL

Terapeutisk grupp:

MONTELUKAST

Terapiområde:

MONTELUKAST

Terapeutiska indikationer:

Montair 5 mg is indicated in adult and pediatric patients 6 years of age and older for the prophylaxis and chronic treatment of asthma, including prevention of daytime and nighttime symptoms, the treatment of aspirin-sensitive asthmatic patients, and the prevention of exercise-induced bronchoconstriction.Montair 5 mg is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma.Montair 5 mg and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability.Montair 5 mg is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and pediatric patients 2 years of age and older.

Tillstånd datum:

2016-02-29

Bipacksedel

                                PATIENT LEAFLET IN ACCORDANCE WITH THE
PHARMACISTS’ REGULATIONS
(PREPARATIONS) – 1986
The medicine is dispensed with a doctor’s
prescription only
MONTAIR 4 MG CHEWABLE TABLETS
MONTAIR 5 MG CHEWABLE TABLETS
Each MONTAIR 4 mg tablet contains:
Montelukast (as sodium) 4 mg
Each MONTAIR 5 mg tablet contains:
Montelukast (as sodium) 5 mg
For a list of inactive ingredients and allergens in the
preparation – see section 2 “Important information
regarding some of the ingredients of the medicine”
and section 6 “Additional information”.
READ THE ENTIRE LEAFLET CAREFULLY BEFORE USING THE
MEDICINE.
•
This leaflet contains concise information about
MONTAIR. If you have other questions, ask the
doctor or pharmacist.
•
This medicine has been prescribed for your
treatment. Do not pass it on to others. It may
harm them even if it seems that their medical
condition is similar to yours.
WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD
KNOW ABOUT MONTAIR?
•
SEVERE MENTAL HEALTH PROBLEMS HAVE BEEN
REPORTED IN PEOPLE TAKING MONTAIR or even
after stopping the treatment. This can happen
in people with or without a history of mental
health problems. Stop taking MONTAIR and
immediately tell your doctor if you or your child
are experiencing unusual changes in behavior
or thinking, including any of the following
symptoms:
Agitation, including aggressive behavior or
hostility, attention disorders, bad or vivid
dreams, depression, disorientation (confusion),
feeling of anxiety, irritability, hallucinations
(seeing or hearing non-existing things),
memory impairment, obsessive-compulsive
symptoms, restlessness, sleep-walking,
stuttering, suicidal thoughts and actions
(including suicide), tremor, insomnia,
uncontrolled muscle movements.
1. WHAT IS MONTAIR AND WHAT IS IT USED FOR?
MONTAIR is indicated for the prevention and chronic
treatment of asthma, including prevention of
daytime and nighttime symptoms, treatment of
aspirin-sensitive asthmatic patients and prevention
of exercise-induced bronchoconstriction in adult
patient
                                
                                Läs hela dokumentet
                                
                            

Dokument på andra språk

Bipacksedel Bipacksedel arabiska 11-01-2023
Bipacksedel Bipacksedel hebreiska 17-08-2016

Sök varningar relaterade till denna produkt

Visa dokumenthistorik